CATALENT INC.

ISIN: US1488061029 WKN: 148806102 Asset Class: Stock



Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Financial figures, Fiscal year: from 01.07. to 30.06.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	2,692,000,000		2,916,000,000		2,918,000,000	
Common stock capital		2,000,000		2,000,000		2,000,000
Fixed assets	8,085,000,000		7,591,000,000		6,194,000,000	
Equity capital of a company		4,611,000,000		4,795,000,000		4,274,000,000
Cash and cash equivalents	280,000,000		449,000,000		896,000,000	
Accrued liabilities		100,000,000		103,000,000		137,000,000
Other assets	-		-		-	
Current liabilities		1,530,000,000		1,072,000,000		1,196,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		4,636,000,000		4,640,000,000		3,642,000,000
Different income		-		-		-
Other liabilities		92,000,000		79,000,000		102,000,000
Total assets	10,777,000,000	10,777,000,000	10,507,000,000	10,507,000,000	9,112,000,000	9,112,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	17,800	19,000	17,300
Equity ratio	42.79%	45.64%	46.91%
Debt-equity ratio	133.72%	119.12%	113.20%

Others			
	2023	2022	2021
Tax Expense Rate	25.15%	14.21%	18.18%

CATALENT INC.

ISIN:	US1488061029	WKN:	148806102	Asset Class:	Stock

Income statement

	2023	2022	2021
Turnover	4,263,000,000	4,828,000,000	3,998,000,000
Net income	-256,000,000	503,000,000	529,000,000
EBIT	-144,034,800	672,162,400	761,722,500
Operating income before taxes	-342,000,000	605,000,000	715,000,000
Cash Flow	254,000,000	439,000,000	433,000,000
Net interest income	-186,000,000	-123,000,000	-110,000,000
Research and development expenses	18,000,000	23,000,000	21,000,000
Income taxes	-86,000,000	86,000,000	130,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	221,125	234,615	213,373

Board of Directors

Members of Management Board

John Greisch	Chairman of Board of Directors
Donald Morel	Member of Board of Directors
Frank D'Amelio	Member of Board of Directors
Gregory Lucier	Member of Board of Directors
J. Carroll	Member of Board of Directors
Jack Stahl	Member of Board of Directors
Michael Barber	Member of Board of Directors
Michelle Ryan	Member of Board of Directors
Rolf Classon	Member of Board of Directors
Stephanie Okey	Member of Board of Directors
Steven Barg	Member of Board of Directors
Alessandro Maselli	Chairman of Managing Board
Charles Lickfold	Member of Executive Committee
Joseph A. Ferraro	Member of Executive Committee
Karen Santiago	Member of Executive Committee
Lisa Evoli	Member of Executive Committee
Matti Masanovich	Member of Executive Committee
Ricky Hopson	Member of Executive Committee